Survodutide(2805997-46-8)Tirz Cagrilintide/Sema/Reta Peptides Weight Loss Peptide 10mg 15mg 30mg Fast Shipping
TDS 6 Inquiries
2805997-46-8
Pharmaceutical Grade
99%
shenzhen
RL
0.05kg/box
2027-12-30
Peptide,retatrutide,Semaglutide
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionCertificates
-
TDS
Basic Info-
Product Name:
Survodutide
Other Name:Survodutide;BI 456906;Survodutide Peptide;Survodutide(BI 456906) 10MG;Survodutide acetate;Suvorouti;Swertide peptide;Suvodutide
CAS No.:2805997-46-8
Molecular Weight:0
EC Number:997-146-8
Color/Form:White to off-white
Categories:
Research-
Class:
Amylin receptor (AMYR) / calcitonin receptor (CTR) agonist (long-acting amylin analog)
Status:Investigational — Phase 3 (REDEFINE program, CagriSema combination)
Mechanism:A novel long-acting, acylated amylin (islet amyloid polypeptide, IAPP) analog consisting of 38 amino acids. Cagrilintide activates the amylin receptor (AMYR) and calcitonin receptor (CTR), reducing food intake, delaying gastric emptying, and promoting satiety. Being developed as monotherapy and in fixed-dose combination with semaglutide (CagriSema) for obesity. Administered once weekly.
Activity note:Cagrilintide is a non-selective AMYR/CTR agonist. Specific EC50 values not publicly available; functional potency is comparable to native amylin at AMYR.
Source:MCE: Cagrilintide (CAS 1415456-99-3); Novo Nordisk REDEFINE program.
Clinical Development:
References-
PubChem:Literature:
MCE: Cagrilintide (CAS 1415456-99-3); ClinicalTrials.gov: REDEFINE-1 (NCT05249895); Novo Nordisk: EASD 2025 Cagrilintide data presentation
Disclaimer:Cagrilintide is NOT FDA-approved or EMA-approved. It is in Phase 3 clinical trials (REDEFINE program). This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Peptide,retatrutide,Semaglutide
-
Location:
Room 2008, 20th Floor, Unit 2, Building 15, No. 152, Dongsanmalu, Guancheng Hui District, Zhengzhou City, Henan Province
-
Average lead Time:
15
-
Total Annual Revenue:
Less than $1 million
-
Total Employees:
11-50
-
Year of Establishment:
2024
-
-
Inquiry History6 Inquiries
Country Product Purchase Quantity Date Posted
United States
Survodutide cas 2805997-46-8
2 MT Nov 14, 2025
United States
Survodutide
10 MG Oct 7, 2024
United States
Survodutide 10MG
10 MG Nov 17, 2025
Ecuador
Survodutide
10 MG Jun 17, 2026
United States
urvodutide
10 G Aug 10, 2025
Bangladesh
Survodutide
1 KG Jul 3, 2024 Post an enquiry for this product
.
put...